LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

298.65 -2.98

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

296.12

Max

307.61

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.5M 56M
Verkäufe	9.3M 116M
KGV Branchendurchschnitt	40.057 50.102
EPS	1.83
Gewinnspanne	48.069
Angestellte	295
EBITDA	16M 55M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+4.2% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	816M 8.8B
Vorheriger Eröffnungskurs	301.63
Vorheriger Schlusskurs	298.65

Nachrichtenstimmung

By Acuity

50%

153 / 344 Ranking in Healthcare

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. Juni 2026, 23:38 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. Juni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. Juni 2026, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. Juni 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. Juni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. Juni 2026, 21:22 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. Juni 2026, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. Juni 2026, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares $11 Special Div

1. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. Juni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. Juni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. Juni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. Juni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. Juni 2026, 18:54 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. Juni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. Juni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. Juni 2026, 18:00 UTC

Akquisitionen, Fusionen, Übernahmen

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. Juni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. Juni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 17:10 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

4.2% Vorteil

12-Monats-Prognose

Durchschnitt 322 USD 4.2%

Hoch 378 USD

Tief 284 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Stimmung

By Acuity

153 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.